FDA approves Aurobindo’s azelastine hydrochloride nasal spray
EAST WINDSOR, N.J. – Aurobindo Pharma has gotten final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Application azelastine hydrochloride nasal spray 0.15% (205.5 mcg per spray). Aurobindo Pharma’s azelastine hydrochloride nasal spray 0.15% (205.5 mcg per spray) are an AB-rated generic equivalent to the reference listed drug (RLD), Astepro
